about
Development of a metabolically active, non-replicating sporozoite vaccine to prevent Plasmodium falciparum malariaAn Octavalent Lyme Disease Vaccine Induces Antibodies That Recognize All Incorporated ospC Type-Specific SequencesAdvances and hurdles on the way toward a leprosy vaccine.Recent advances in Ebolavirus vaccine developmentSchistosomiasis vaccinesPerformance of rotavirus vaccines in developed and developing countriesA policy framework for accelerating adoption of new vaccinesCommentary: the anthrax vaccine: no new tricks for an old dogComparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 yearsHIV-1 vaccine design: harnessing diverse lymphocytes to conquer a diverse pathogenChallenges and opportunities in the Israeli 2009 pandemic influenza vaccination program.Vaccine development for an imminent pandemic: why we should worry, what we must do.Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.A call to cellular & humoral arms: enlisting cognate T cell help to develop broad-spectrum vaccines against influenza A.Vaccination strategies and vaccine formulations for epidemic and pandemic influenza control.Attenuated poxvirus vectors MVA and NYVAC as promising vaccine candidates against HIV/AIDS.Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.The Spanish human papillomavirus vaccine consensus group: a working model.Predictors of influenza vaccination uptake among adults with a history of heart attack.Public health measures & individualized decision-making: The confluence of the H1N1 vaccine and Islamic bioethics.China's emerging vaccine industry.Pandemic influenza A 2009 (H1N1) vaccination in high risk children with chronic renal diseases: acceptance and perceptions.Dried influenza vaccines: over the counter vaccines.Pre-pandemic and pandemic influenza vaccines.Similar immunogenicity of the A/H1N1 2009 pandemic influenza strain when used as a monovalent or a trivalent vaccine.Immunogenicity and safety of a novel AS03(A)-adjuvanted H1N1 2009 pandemic influenza vaccine in adults in Japan.Adjuvants and alternative routes of administration towards the development of the ideal influenza vaccine.The 2009 H1N1 influenza pandemic: a case study of how modeling can assist all stages of vaccine decision-makingPlant-based rapid production of recombinant subunit hemagglutinin vaccines targeting H1N1 and H5N1 influenza.Haemophilus influenzae vaccine candidate outer membrane protein P6 is not conserved in all strains.Assessment of the safety, tolerability and kinetics of the immune response to A/H1N1v vaccine formulations with and without adjuvant in healthy pediatric subjects from 3 through 17 years of age.Differences in sentinel influenza confirmed incidence rates and clinical presentation of influenza virus: 2008-09 seasonal vs 2009-10 pandemic influenza.Epidemiological analysis of severe hospitalized 2009 pandemic influenza A (H1N1) cases in Catalonia, Spain.Uptake of 2009 H1N1 vaccine among adolescent females.Cross-protective immunity against influenza virus infections induced by intranasal vaccination together with a TLR3-mucosal adjuvant.Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations.Increasing pandemic vaccination rates with effective communication.Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in children and adolescents with Williams or Cornelia De Lange syndrome.The evaluation of the opinions and attitudes of healthcare personnel of the province Diyarbakir against influenza A (H1N1) and the vaccination.An influenza N1 neuraminidase-specific monoclonal antibody with broad neuraminidase inhibition activity against H5N1 HPAI viruses.
P1433
Q21032534-BE00F7CD-2707-4464-ABEE-63632D8C5CCBQ22241092-11BB73E9-1859-4C02-8089-7A4CA5AF336AQ22305432-1DC97DD5-6848-42D7-854D-E0F510FBCCDEQ22305433-ADAB3E93-DDCF-48D5-ABB7-BBA9778D2FDEQ24598949-A52CAA7A-D13B-4036-BC62-DAA18108A5D7Q24600612-6B5BF35D-61C1-426B-95AC-83F309AC4300Q24634001-FA5DCC5A-C06E-4B92-B897-6E6ED3A921C6Q24704274-52B22578-E82E-4142-B319-FB37FB7D391FQ28255234-BAE34FBC-2C93-41FF-BC4F-7E7D491F7A28Q28390427-4F3A913B-5C84-43D5-82D5-7BC2303748D3Q30224975-21C50909-A6ED-44BA-BC38-C5FB43E0BA0FQ30357168-E56E1C72-1D73-4BFC-A6B0-B4A810B9FDB1Q30362939-C647E4F6-AA8F-4959-9FAD-D29045527351Q30368604-5241B85B-A483-4C79-BF91-2C4BAB9A2BC9Q30372918-B124D799-F46B-43A7-9B29-46317C806F48Q30381133-33C777BD-A423-404C-8D4F-6DE6D4D5FB9CQ30382097-628A9C8F-6B62-4AA1-976B-F2387916EF26Q30389419-FD627227-1EE6-45CC-91A8-3DB63A168074Q30389936-F9E135DF-5775-4636-ACE2-11BA5751DB5BQ30389940-0AE03DD9-A6A2-430F-8D00-5CA4683C969DQ30389995-A032D67E-3F18-4DF0-88F1-4682C0C1968CQ30394647-846A40BB-4602-4D09-85EF-989D76F0454AQ30394651-B04FA24D-E9F6-4A46-9396-FD7B8DD1303CQ30394742-CAB6B613-C9E6-4391-9A55-DE2A428A6485Q30394744-F8DCF22D-0794-420E-B5E5-0E72AC8CE15AQ30395352-E645E738-FDE5-45B6-B347-AFF4483CF5E8Q30398693-8FD78217-EB38-416E-9CDC-DE7DEBEFA88EQ30398941-856D4DF1-DBAA-4AFB-AD89-59C6F5D8D786Q30398983-ABEE5191-20EF-4477-B799-FB9296824A32Q30399213-32E25049-3AE6-4841-99CC-796D5B2D53C7Q30399216-A4C75CC6-2882-42CE-A3CB-448674CF9376Q30399220-36FC4CC6-2DCF-4844-B2E5-293B3B037D60Q30399428-1CD0ED36-A1DD-4F14-9AA9-37FDD8A22A86Q30399506-6BD01116-4F76-40CC-A011-33CF07A7335EQ30399691-274A9A3D-0467-45B2-B6F1-05D785C5009CQ30400980-586C58CF-5E55-459C-A873-BA13982F9132Q30401231-3B48235F-F67D-4EC6-8482-50ECCC82211FQ30402050-E179BA0E-5C60-4C56-95CB-B865886F8781Q30406727-00DCE896-EE25-440B-9A3A-34FBDDDF358AQ30407144-7BEA8F13-E629-4D37-89D6-CEE762706F12
P1433
description
journal
@en
revista científica
@es
rivista scientifica
@it
vědecký časopis
@cs
wetenschappelijk tijdschrift van Landes Bioscience
@nl
wissenschaftliche Fachzeitschrift
@de
مجلة
@ar
name
Human Vaccines
@ast
Human Vaccines
@en
Human Vaccines
@es
Human Vaccines
@it
Human Vaccines
@nl
type
label
Human Vaccines
@ast
Human Vaccines
@en
Human Vaccines
@es
Human Vaccines
@it
Human Vaccines
@nl
prefLabel
Human Vaccines
@ast
Human Vaccines
@en
Human Vaccines
@es
Human Vaccines
@it
Human Vaccines
@nl
P3181
P1055
P1058
P1156
4400151410
P1476
Human Vaccines
@und